FDA AERS – Ojemda (Tovorafenib) by Day One Biopharmaceuticals (From 1/1/24; PDF/Excel; Investment FOIA)

• Status: Pending Fast-Track Request
• Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.